Centessa Pharmaceuticals PLC
CNTA22.970USD
+1.120+5.13%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
3.08BMarket Cap
LossP/E TTM
More Details of Centessa Pharmaceuticals PLC Company
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Company Info
Ticker SymbolCNTA
Company nameCentessa Pharmaceuticals PLC
IPO dateMay 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
Number of employees77
Security typeDepository Receipt
Fiscal year-endMay 28
Address3rd Floor
CityALTRINCHAM
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited Kingdom
Postal codeWA14 2DT
Phone447391789784
Websitehttps://www.centessa.com/
Ticker SymbolCNTA
IPO dateMay 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen Anderson
Ms. Karen Anderson
Chief People Officer
Chief People Officer
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Sep 8
Updated: Mon, Sep 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
14.89%
Index Ventures SA
7.43%
General Atlantic LLC
7.22%
Adage Capital Management, L.P.
6.27%
Janus Henderson Investors
4.87%
Other
59.32%
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
14.89%
Index Ventures SA
7.43%
General Atlantic LLC
7.22%
Adage Capital Management, L.P.
6.27%
Janus Henderson Investors
4.87%
Other
59.32%
Shareholder Types
Shareholders
Proportion
Hedge Fund
23.29%
Venture Capital
22.97%
Investment Advisor
18.60%
Investment Advisor/Hedge Fund
18.04%
Private Equity
9.01%
Research Firm
1.74%
Individual Investor
0.48%
Pension Fund
0.04%
Other
5.83%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
222
133.71M
100.08%
-10.95M
2025Q1
222
135.75M
101.62%
-10.84M
2024Q4
187
130.97M
99.33%
-6.00M
2024Q3
166
123.88M
97.57%
+8.26M
2024Q2
145
101.97M
89.71%
-3.69M
2024Q1
140
90.07M
89.09%
-8.60M
2023Q4
126
85.94M
86.60%
-9.82M
2023Q3
125
84.37M
86.02%
-11.03M
2023Q2
135
82.21M
85.98%
-8.96M
2023Q1
131
78.75M
82.92%
-8.68M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Medicxi Ventures (UK) LLP
19.96M
14.94%
--
--
Apr 24, 2025
Index Ventures SA
9.96M
7.46%
--
--
Apr 24, 2025
General Atlantic LLC
9.68M
7.25%
--
--
Apr 24, 2025
Adage Capital Management, L.P.
6.95M
5.2%
+1.83M
+35.85%
Mar 31, 2025
Janus Henderson Investors
5.92M
4.43%
+1.01M
+20.63%
Mar 31, 2025
T. Rowe Price Associates, Inc.
5.34M
4%
-22.05K
-0.41%
Mar 31, 2025
Avoro Capital Advisors LLC
4.05M
3.03%
+4.05M
--
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.33M
3.24%
+835.61K
+23.88%
Mar 31, 2025
First Light Asset Management, LLC
4.87M
3.65%
-931.06K
-16.04%
Mar 31, 2025
VV Manager LLC
3.93M
2.95%
--
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
